Wrinkle / Line · Glabellar lines
Botulinum toxin a evidence for Glabellar lines
This procedure group has the highest level of PubMed evidence for this indication, and the papers broadly support its effectiveness.
Grade combines the quantity and quality of the research, while direction is a separate signal showing how the papers assess effectiveness.
Includes meta-analysis/SR Median year 2018 Last 5 years 37% Positive results 59% Negative results 16 Korea/Asia 31
Known in Korea as
Procedure and brand names vary, but the evidence above applies to the same procedure mechanism.
Key papers
tier1 Is Ready-To-Use AbobotulinumtoxinA More Effective Than OnabotulinumtoxinA for Glabellar Lines? A Randomized, Controlled, Triple-Blinded Clinical Trial.
Abstract summary (English) BACKGROUND: Most commercially available botulinum toxin A (BoNT-A) formulations are lyophilized or vacuum-dried powders requiring reconstitution. Recently a ready-to-use formulation (RTUaboBoNT-A) has been introduced. Although its efficacy in reducing glabellar lines has been reported, comparative data with powder onabotulinumtoxinA (OnaBoNT-A) remain limited.
Journal Article, Randomized Controlled Trial, Comparative Study
View on PubMedtier1 NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
Abstract summary (English) BACKGROUND: Botulinum neurotoxins in aesthetic medicine require reconstitution, which may cause administration errors. OBJECTIVE: To evaluate liquid nivobotulinumtoxinA treatment of lateral canthal lines (LCL) and glabellar lines (GL). MATERIALS AND METHODS: Participants with moderate-to-severe LCL with/without moderate-to-severe GL were enrolled in 2 double-blind randomized clinical trials.
Journal Article, Randomized Controlled Trial
View on PubMedtier1 Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines.
Abstract summary (English) BACKGROUND/OBJECTIVES: Two Phase III randomized controlled trials were conducted in the US (ULTRA I) and Germany (ULTRA II) to investigate the efficacy of incobotulinumtoxinA for simultaneous treatment of upper facial lines (UFLs: glabellar frown lines [GFLs], horizontal forehead lines [HFLs] and lateral canthal lines [LCLs]). PATIENTS/METHODS: Healthy adults with moderate to severe GFLs, HFLs, and symmetrical LCLs...
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
View on PubMedtier1 Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.
Abstract summary (English) BACKGROUND: RelabotulinumtoxinA (relaBoNT-A; Relfydess, Galderma, Uppsala, Sweden) is a novel, ready-to-use liquid form of botulinum toxin A, created using PEARL technology to produce a highly effective, complex-free formulation. OBJECTIVES: This study reports the patient-assessed effectiveness and satisfaction outcomes from the relaBoNT-A Phase 3 READY-1 study. METHODS: Adults with moderate-to-severe glabellar...
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
View on PubMedtier1 Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial.
Abstract summary (English) BACKGROUND: Botulinum toxin is a key treatment for dynamic wrinkles. OBJECTIVE: This study evaluates CKDB-501A, a botulinum toxin completely free from animal-derived components including human-serum albumin, comparing its efficacy and safety to onabotulinumtoxinA (ONA) for the treatment of moderate-to-severe glabellar lines. METHODS: In this phase 3 trial, 300 subjects with moderate-to-severe glabellar lines were...
Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Comparative Study
View on PubMedtier1 Comparing Ready-to-Use and Powder AbobotulinumtoxinA for Glabellar Lines: A Randomized, Controlled, Triple-Blinded Clinical Trial.
Abstract summary (English) BACKGROUND: Botulinum toxin A (BoNT-A) is the most used procedure to treat glabellar lines; however, limited data exist about the effectiveness of ready-to-use BoNT-A (RTUaboBoNT-A) for this indication. AIMS: This study compared the efficacy, durability, and safety of RTUaboBoNT-A for moderate and severe glabellar wrinkles. METHODS: This randomized triple-blinded trial included 38 male volunteers aged between 25 and...
Journal Article, Randomized Controlled Trial, Comparative Study
View on PubMedtier1 Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19.
Abstract summary (English) MBA-P01 is a newly developed botulinum toxin A (BoNT-A) product designed to provide similar clinical effects as OnabotulinumtoxinA (ONA-BoNT-A), thereby providing an alternative treatment option for glabellar lines. It is another holotoxin preparation containing BoNT-A1. This randomized, double-blind, active-controlled, multi-center, Phase III clinical trial aimed to evaluate the efficacy and safety of MBA-P01...
Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study
View on PubMedtier1 NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.
Abstract summary (English) BACKGROUND: Botulinum neurotoxins in aesthetic medicine require reconstitution before administration, which may be inconvenient and present errors among injectors. OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of ready-to-use nivobotulinumtoxinA liquid formulation for the treatment of glabellar lines (GL) with or without treatment of lateral canthal lines (LCL). METHODS: Two multicenter,...
Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial
View on PubMedtier1 IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Abstract summary (English) BACKGROUND: Two randomized, double-blind, placebo-controlled, Phase III studies of incobotulinumtoxinA for treating upper facial lines (UFLs; ie, a combination of glabellar frown lines [GFLs], horizontal forehead lines [HFLs], and lateral canthal lines [LCLs]) were conducted in the United States (ULTRA I: NCT04594213) and Germany (ULTRA II: NCT04622254). OBJECTIVES: The aim of this study was to evaluate the safety...
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
View on PubMedtier1 Meta-Analysis of Adverse Reactions of Botulinum Toxin A in Facial Rejuvenation Treatment.
Abstract summary (English) BACKGROUND: Facial rejuvenation is a popular non-surgical treatment, and its treatment safety is of key significance to patients. The purpose of this meta-analysis is to compare the effects of botulinum toxin A and placebo on the occurrence of adverse reactions in facial rejuvenation treatment. OBJECTIVE: According to PRISMA guidelines, a comprehensive search was conducted in Chinese and English databases, and 20...
Journal Article, Meta-Analysis
View on PubMedPersonalized evidence report
Tell us more about your concern
and the Glass Lab bot will build a personalized report for you.
Based on the Botulinum toxin a · Glabellar lines information on this page, we'll email you an evidence summary tailored to your skin condition and treatment stage.